Raymond James on Humana (HUM): 'Medicaid Fears Didn't Surface, and Core Guide Raise Better Than It Appears'

Go back to Raymond James on Humana (HUM): 'Medicaid Fears Didn't Surface, and Core Guide Raise Better Than It Appears'

Humana (HUM) PT Lowered to $277 at Morgan Stanley

July 31, 2025 8:29 AM EDT

Morgan Stanley analyst Erin Wright lowered the price target on Humana (NYSE: HUM) to $277.00 (from $290.00) while maintaining a Equalweight rating.... More

Humana (HUM) PT Lowered to $272 at Piper Sandler

July 31, 2025 7:28 AM EDT

Piper Sandler analyst Jessica Tassan lowered the price target on Humana (NYSE: HUM) to $272.00 (from $288.00) while maintaining a Neutral rating.... More

Humana (HUM) PT Raised to $280 at Truist Securities

July 31, 2025 7:17 AM EDT

Truist Securities analyst David MacDonald raised the price target on Humana (NYSE: HUM) to $280.00 (from $260.00) while maintaining a Hold rating.... More

Humana (HUM) PT Raised to $275 at Barclays

July 31, 2025 3:34 AM EDT

Barclays analyst Andrew Mok raised the price target on Humana (NYSE: HUM) to $275.00 (from $268.00) while maintaining a Equalweight rating.... More